Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Daniela Weisenberger"'
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Antibodies that target a clinically relevant group of receptors within the tumor necrosis factor receptor superfamily (TNFRSF), including CD40 and CD95 (Fas/Apo-1), also require binding to Fc gamma receptors (FcγRs) to elicit a strong agonistic acti
Externí odkaz:
https://doaj.org/article/12c751e24e6048bbbd2bbeab4bb47e27
Autor:
José Antonio Carmona Arana, Johannes Trebing, Viktoria Schäfer, Harald Wajant, Agnes Wyzgol, Isabell Lang, Andrea Fick, Simone Füllsack, Daniela Weisenberger
Publikováno v:
The Journal of biological chemistry. 295(32)
Ligands of the tumor necrosis factor superfamily (TNFSF) interact with members of the TNF receptor superfamily (TNFRSF). TNFSF ligand-TNFRSF receptor interactions have been intensively evaluated by many groups. The affinities of TNFSF ligand-TNFRSF r
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Antibodies that target a clinically relevant group of receptors within the tumor necrosis factor receptor superfamily (TNFRSF), including CD40 and CD95 (Fas/Apo-1), also require binding to Fc gamma receptors (FcγRs) to elicit a strong agonistic acti
Autor:
Anne Deuretzbacher, Elke Baumeister, Andreas Beilhack, Markus Kapp, Harald Wajant, Carolin Köchel, Nergui Dagvadorj, Daniela Weisenberger, Isabell Lang, Johannes Trebing, Kerstin Kapp, Thomas Hünig, Hermann Einsele, Götz Ulrich Grigoleit
Publikováno v:
Cancer Immunology, Immunotherapy. 66:319-332
Due to its immunogenicity and overexpression concomitant with leukemia progression, Wilms tumor protein 1 (WT1) is of particular interest for immunotherapy of AML relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). So far, W
Autor:
Daniela Weisenberger, Johannes Nelke, Moritz Rothaug, Susanne Berr, Tim Steinfatt, Juliane Medler, Andreas Beilhack, Harald Wajant, Thomas Hünig
Publikováno v:
Cell Death & Disease
Cell Death and Disease, Vol 10, Iss 3, Pp 1-13 (2019)
Cell Death and Disease, Vol 10, Iss 3, Pp 1-13 (2019)
Antibodies specific for TNFRSF receptors that bind soluble ligands without getting properly activated generally act as strong agonists upon FcγR binding. Systematic analyses revealed that the FcγR dependency of such antibodies to act as potent agon
Autor:
Harald Wajant, Andrea Fick, Agnes Wyzgol, Daniela Weisenberger, José Antonio Carmona Arana, Simone Füllsack, Johannes Trebing, Viktoria Schäfer, Isabell Lang
Publikováno v:
J Biol Chem
Ligands of the tumor necrosis factor superfamily (TNFSF) interact with members of the TNF receptor superfamily (TNFRSF). TNFSF ligand-TNFRSF receptor interactions have been intensively evaluated by many groups. The affinities of TNFSF ligand-TNFRSF r
Autor:
Johannes Trebing, Manfred Neumann, Isabell Lang, Daniela Weisenberger, Harald Wajant, José Antonio Carmona Arana, Alevtina Rosenthal, Daniela Siegmund, Steffen Salzmann, Viktoria Schäfer
Publikováno v:
The Journal of Immunology. 191:2308-2318
We found recently that TNF-like weak inducer of apoptosis (TWEAK) and fibroblast growth factor–inducible-14 (Fn14) by virtue of their strong capability to reduce the freely available cytoplasmic pool of TNFR-associated factor (TRAF)2 and cellular i
Autor:
Johannes Trebing, Harald Wajant, Daniela Siegmund, Daniela Weisenberger, Axel Seher, Alevtina Rosenthal, Steffen Salzmann
Publikováno v:
Journal of Biological Chemistry. 288:13455-13466
Fn14 is a therapeutic target in various diseases.Anti-Fn14 antibodies activate the alternative NFκB pathway but not other Fn14-related activities induced by soluble or membrane-bound TWEAK. FcγR-bound anti-Fn14 antibodies, however, activate the ful
Autor:
Nergui, Dagvadorj, Anne, Deuretzbacher, Daniela, Weisenberger, Elke, Baumeister, Johannes, Trebing, Isabell, Lang, Carolin, Köchel, Markus, Kapp, Kerstin, Kapp, Andreas, Beilhack, Thomas, Hünig, Hermann, Einsele, Harald, Wajant, Götz Ulrich, Grigoleit
Publikováno v:
Cancer immunology, immunotherapy : CII. 66(3)
Due to its immunogenicity and overexpression concomitant with leukemia progression, Wilms tumor protein 1 (WT1) is of particular interest for immunotherapy of AML relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). So far, W
Autor:
Daniela Weisenberger, Harald Wajant, Johannes Trebing, Mohamed El-Mesery, Karen Silence, Viktoria Schäfer, Daniela Siegmund
Publikováno v:
Cell Death & Disease
To combine the CD27 stimulation inhibitory effect of blocking CD70 antibodies with an antibody-dependent cellular cytotoxicity (ADCC)-independent, cell death-inducing activity for targeting of CD70-expressing tumors, we evaluated here fusion proteins